For the nearly 2,000 volunteers in SILCAAT, there have been a few changes in how the study is conducted. Some minor changes have been made in the study.
What's perhaps most important to note is that Chiron's decision to stop SILCAAT was not a scientific decision, but rather a business decision. Typically decisions about stopping a study happen because the study is unable to answer the scientific question it set out to answer or because one of the study groups is doing markedly better or worse than the other(s). To the contrary in this instance, the study is in midstride and progressing toward answering the question in the expected timeframe. It's extremely unusual for a company to stop when everything is proceeding as planned and expected.
Bluntly, Chiron simply didn't want to pay for the study and used people living with HIV and the importance of this research question as a financial pawn. At the end of the day, Chiron will continue to provide some greatly reduced funding to enable the project to continue. The task of running the study and managing the information has been turned over to independent investigators.
This certainly doesn't make Chiron any great hero. Their business decision to pull support from this study is an affront to people living with HIV at best, and morally corrupt at worst. In facing perhaps the greatest plague in human history, Chiron leadership turned its back. Particular kudos goes to Dr. Jim Neaton at the University of Minnesota and Dr. Cliff Lane at the National Institutes of Health for their leadership in ensuring that SILCAAT continues.